AP1G1 and viral infectious disease: Importantly, we found that the patent medicine Shufengjiedu (SFJD can significantly reduce the susceptibility of host cells to viral infection through this mechanism, providing evidence for the practicability of SLC16A3-AP1G1 strategy.